MicroT Biotech has raised over $50 million in Series A and A+ financing to advance GT801, its CD19-targeting in vivo CAR-T candidate. The deal highlights growing institutional interest in scalable cell therapy platforms amid rising global M&A activity in the in vivo CAR-T space.